Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV

British Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2002, Pages 178-182

  Moyle, G J ^a,c   Buss, N E ^a   Goggin, T ^a   Snell, P ^b   Higgs, C ^c   Hawkins, D A ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

CYP3A; HIV; Interaction; Pharmacokinetics; Rifabutin; Saquinavir

Indexed keywords

RIFABUTIN; SAQUINAVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; FEVER; GASTROINTESTINAL SYMPTOM; GEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIGRAINE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SWEATING; VOMITING;

ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RIFABUTIN; SAQUINAVIR;

EID: 0036037490     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01631.x     Document Type: Article

References (18)

1. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
2. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 cell count following highly active antiretroviral therapy
3. Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
4. + T-lymphocyte count
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies
7. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents
8. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
9. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
10. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
11. Interactions with antiretroviral drugs
12. Update on results from drug-interaction studies with rifabutin
13. Anterior uveitis in HIV-infected patients. Three cases in patients treated with an antiprotease
14. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
15. Ritonavir enables combined therapy with rifampin and saquinavir
16. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus
17. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period
18. Chromatographic and immunochemical approaches to the analysis of the HIV protease inhibitor saquinavir in plasma